Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Cost per Progression Free Survival (PFS) of Daratumumab, Elotuzumab, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (DRd, ERd, KRd, IRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Pamela Santana, Ricardo Saad, MSc, Adrielle Kolanian, Cyntia Fioratti, Marcela Junqueira, Tassia Decimoni, MSc

Blood (2019) 134 (Supplement_1): 3149.

https://doi.org/10.1182/blood-2019-131742

Published: 2019

Journal Articles

Patient-Reported Outcome Labeling for Malignant Hematology Drugs Approved in the United States: 2011-2017

Marjorie E Zettler, PhD MPH, Ethan Basch, MD MSc, Chadi Nabhan, MD

Blood (2018) 132 (Supplement 1): 2292.

https://doi.org/10.1182/blood-2018-99-116404

Published: 2018

Journal Articles

Treatment Patterns and Outcomes Among Patients with Higher-Risk Myelodysplastic Syndromes Treated in a Real-World Setting: Electronic Medical Record-Based Data

Jill A Bell, PhD, Aaron Galaznik, MD, Eileen Farrelly, MPH, Marlo Blazer, PharmD, BCOP, Brian Seal, RPh, MBA, PhD, Huai-Che Shih, PhD, Augustina Ogbonnaya, MPH, Michael Eaddy, PharmD, PhD, Bruce J Dezube, MD

Blood (2016) 128 (22): 5540.

https://doi.org/10.1182/blood.V128.22.5540.5540

Published: 2016

Journal Articles

A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure

Aziz Nazha, MD, Rami S. Komrokji, MD, Guillermo Garcia-Manero, MD, John Barnard, PhD, Katrina Zell, MA, MS, Cassie Zimmerman, MPH, Najla H. Al Ali, BDS, MSc, Gail J Roboz, MD, David P. Steensma, MD, Amy E. DeZern, MD MHS, Eric Padron, MD, Elias J. Jabbour, MD, Molly Dara Greenberg, BS, Alan F. List, MD, Hagop M. Kantarjian, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2015) 126 (23): 2888.

https://doi.org/10.1182/blood.V126.23.2888.2888

Published: 2015

Journal Articles

Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA+) According to the MRC Risk Index Score

Blood (2015) 126 (23): 2554.

https://doi.org/10.1182/blood.V126.23.2554.2554

Published: 2015

Journal Articles

The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure

Aziz Nazha, MD, Rami S Komrokji, MD, Guillermo Garcia-Manero, MD, John Barnard, Cassie Zimmerman, MA, Al Ali Najla, Gail J. Roboz, MD, David P. Steensma, MD, Amy E. DeZern, MD MHS, Elias Jabbour, MD, Sangmin Lee, MD, Molly D. Greenberg, B.S., Alan F List, MD, Hagop M. Kantarjian, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2014) 124 (21): 3275.

https://doi.org/10.1182/blood.V124.21.3275.3275

Published: 2014

Journal Articles

Azacitidine As Front-Line Therapy in AML: Results From Spanish National Registry. Alma Study Investigators

Blood (2012) 120 (21): 3593.

https://doi.org/10.1182/blood.V120.21.3593.3593

Published: 2012

Journal Articles

Serious Adverse Drug Reactions (sADRS) Associated with Hematopoietic Growth Factors: A Systematic Review From the Southern Network on Adverse Reactions (SONAR) Program

LeAnn Norris, PharmD, Zaina Qureshi, PhD, MPH, Sara Barnato, Stephen Lai, MD, PhD, Charles Bennett, MD, PhD, MPP

Blood (2010) 116 (21): 2555.

https://doi.org/10.1182/blood.V116.21.2555.2555

Published: 2010

Journal Articles

Treatment of a B-Cell, Primary Central Nervous System Lymphoma Patient with Radioimmunotherapy Using Zevalin®: A Proof-of-Principal Case.

Ruby Meredith, MD, Louis Nabors, MD, Sui Shen, PhD, John Fiveash, MD, Sthepen Besh, MD, PhD, Albert LoBuglio, MD, Andres Forero-Torres, MD

Blood (2004) 104 (11): 4639.

https://doi.org/10.1182/blood.V104.11.4639.4639

Published: 2004

Journal Articles

Osteonecrosis of the Jaw in Myeloma Patients Receiving Pamidronate or Zoledronate.

Victoria Kut, MD, J. Mehta, MD, J. Tariman, MSN, A. Olsson, DDS, S. Singhal, MD

Blood (2004) 104 (11): 4933.

https://doi.org/10.1182/blood.V104.11.4933.4933

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Cost per Progression Free Survival (PFS) of Daratumumab, Elotuzumab, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (DRd, ERd, KRd, IRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Patient-Reported Outcome Labeling for Malignant Hematology Drugs Approved in the United States: 2011-2017

Treatment Patterns and Outcomes Among Patients with Higher-Risk Myelodysplastic Syndromes Treated in a Real-World Setting: Electronic Medical Record-Based Data

A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure

Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA+) According to the MRC Risk Index Score

The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure

Azacitidine As Front-Line Therapy in AML: Results From Spanish National Registry. Alma Study Investigators

Serious Adverse Drug Reactions (sADRS) Associated with Hematopoietic Growth Factors: A Systematic Review From the Southern Network on Adverse Reactions (SONAR) Program

Treatment of a B-Cell, Primary Central Nervous System Lymphoma Patient with Radioimmunotherapy Using Zevalin®: A Proof-of-Principal Case.

Osteonecrosis of the Jaw in Myeloma Patients Receiving Pamidronate or Zoledronate.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only